Davis Jason 4

What Happened

• Jason Davis, Chief Financial Officer of FibroBiologics, purchased 70,000 shares of FBLG in an open-market transaction on March 2, 2026. The reported weighted-average price was $0.41 per share for a total cash outlay of about $28,973. This was a direct purchase (transaction code P), which investors often view as a more informative (potentially bullish) signal than routine sales.

Key Details

• Transaction date: 2026-03-02; filing date: 2026-03-03 (filed the next day).
• Reported price: weighted average $0.41 per share; actual trades ranged from $0.3968 to $0.4200 (see footnote).
• Total shares acquired: 70,000; total reported value: $28,973.
• Shares owned after the transaction: not specified in the public Form 4 filing.
• Footnote: The $0.41 figure is a weighted average; the reporting person will provide, upon request, the number of shares bought at each separate price.
• Filing timeliness: No late filing indicated (filed one day after the transaction).

Context

• This was an open-market cash purchase (not an option exercise, award, or gift). For retail investors, insider purchases can be a useful signal to watch, but they should be considered alongside company fundamentals and broader trading activity.